Search
Terfenadine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175125Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeAstemizole H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175126Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeGSK-1004723 H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175139Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typePromazine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175142Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeChloropyramine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175097Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeIsothipendyl H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175114Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeTriprolidine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175074Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeCinnarizine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175077Drug actionThis normally activates the Gq signalling cascade which activates phospholipase C which catalyzes the production of Inositol 1,4,5-trisphosphate (IP3) and Diacylglycerol (DAG).
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeBilastine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175116Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeTrazodone H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175143Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha type